vs

Side-by-side financial comparison of John Marshall Bancorp, Inc. (JMSB) and AVITA Medical, Inc. (RCEL). Click either name above to swap in a different company.

AVITA Medical, Inc. is the larger business by last-quarter revenue ($17.6M vs $16.8M, roughly 1.0× John Marshall Bancorp, Inc.). John Marshall Bancorp, Inc. runs the higher net margin — 36.3% vs -66.0%, a 102.3% gap on every dollar of revenue. Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs 15.3%).

John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...

JMSB vs RCEL — Head-to-Head

Bigger by revenue
RCEL
RCEL
1.0× larger
RCEL
$17.6M
$16.8M
JMSB
Higher net margin
JMSB
JMSB
102.3% more per $
JMSB
36.3%
-66.0%
RCEL
Faster 2-yr revenue CAGR
RCEL
RCEL
Annualised
RCEL
26.0%
15.3%
JMSB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
JMSB
JMSB
RCEL
RCEL
Revenue
$16.8M
$17.6M
Net Profit
$6.1M
$-11.6M
Gross Margin
81.2%
Operating Margin
-59.1%
Net Margin
36.3%
-66.0%
Revenue YoY
-4.3%
Net Profit YoY
26.8%
-0.3%
EPS (diluted)
$0.43
$-0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
JMSB
JMSB
RCEL
RCEL
Q1 26
$16.8M
Q4 25
$16.4M
$17.6M
Q3 25
$16.3M
$17.1M
Q2 25
$15.4M
$18.4M
Q1 25
$14.6M
$18.5M
Q4 24
$14.3M
$18.4M
Q3 24
$13.8M
$19.5M
Q2 24
$12.6M
$15.2M
Net Profit
JMSB
JMSB
RCEL
RCEL
Q1 26
$6.1M
Q4 25
$5.9M
$-11.6M
Q3 25
$5.4M
$-13.2M
Q2 25
$5.1M
$-9.9M
Q1 25
$4.8M
$-13.9M
Q4 24
$4.8M
$-11.6M
Q3 24
$4.2M
$-16.2M
Q2 24
$3.9M
$-15.4M
Gross Margin
JMSB
JMSB
RCEL
RCEL
Q1 26
Q4 25
81.2%
Q3 25
81.3%
Q2 25
81.2%
Q1 25
84.7%
Q4 24
87.6%
Q3 24
83.7%
Q2 24
86.1%
Operating Margin
JMSB
JMSB
RCEL
RCEL
Q1 26
Q4 25
47.4%
-59.1%
Q3 25
42.2%
-53.6%
Q2 25
42.7%
-60.5%
Q1 25
42.4%
-63.9%
Q4 24
42.5%
-54.1%
Q3 24
38.8%
-70.6%
Q2 24
39.7%
-102.8%
Net Margin
JMSB
JMSB
RCEL
RCEL
Q1 26
36.3%
Q4 25
36.2%
-66.0%
Q3 25
33.2%
-77.3%
Q2 25
33.1%
-53.9%
Q1 25
32.9%
-74.9%
Q4 24
33.3%
-63.0%
Q3 24
30.7%
-82.9%
Q2 24
30.9%
-101.3%
EPS (diluted)
JMSB
JMSB
RCEL
RCEL
Q1 26
$0.43
Q4 25
$0.41
$-0.37
Q3 25
$0.38
$-0.46
Q2 25
$0.36
$-0.38
Q1 25
$0.34
$-0.53
Q4 24
$0.33
$-0.44
Q3 24
$0.30
$-0.62
Q2 24
$0.27
$-0.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
JMSB
JMSB
RCEL
RCEL
Cash + ST InvestmentsLiquidity on hand
$150.2M
$18.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$268.1M
$-16.6M
Total Assets
$2.4B
$56.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
JMSB
JMSB
RCEL
RCEL
Q1 26
$150.2M
Q4 25
$130.0M
$18.2M
Q3 25
$163.6M
$23.3M
Q2 25
$116.9M
$15.7M
Q1 25
$169.1M
$25.8M
Q4 24
$122.5M
$35.9M
Q3 24
$177.2M
$44.4M
Q2 24
$182.6M
$54.1M
Total Debt
JMSB
JMSB
RCEL
RCEL
Q1 26
Q4 25
$80.9M
Q3 25
$80.9M
Q2 25
$80.8M
Q1 25
$80.8M
Q4 24
$80.8M
Q3 24
$80.8M
Q2 24
$24.7M
Stockholders' Equity
JMSB
JMSB
RCEL
RCEL
Q1 26
$268.1M
Q4 25
$265.6M
$-16.6M
Q3 25
$259.7M
$-6.7M
Q2 25
$253.7M
$-12.9M
Q1 25
$253.0M
$-4.6M
Q4 24
$246.6M
$4.5M
Q3 24
$243.1M
$12.2M
Q2 24
$235.3M
$23.9M
Total Assets
JMSB
JMSB
RCEL
RCEL
Q1 26
$2.4B
Q4 25
$2.3B
$56.4M
Q3 25
$2.3B
$63.7M
Q2 25
$2.3B
$58.1M
Q1 25
$2.3B
$69.6M
Q4 24
$2.2B
$79.7M
Q3 24
$2.3B
$81.1M
Q2 24
$2.3B
$87.8M
Debt / Equity
JMSB
JMSB
RCEL
RCEL
Q1 26
Q4 25
0.30×
Q3 25
0.31×
Q2 25
0.32×
Q1 25
0.32×
Q4 24
0.33×
Q3 24
0.33×
Q2 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
JMSB
JMSB
RCEL
RCEL
Operating Cash FlowLast quarter
$-5.4M
Free Cash FlowOCF − Capex
$-6.1M
FCF MarginFCF / Revenue
-34.7%
Capex IntensityCapex / Revenue
3.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-33.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
JMSB
JMSB
RCEL
RCEL
Q1 26
Q4 25
$22.6M
$-5.4M
Q3 25
$1.2M
$-5.2M
Q2 25
$7.5M
$-10.2M
Q1 25
$7.0M
$-10.3M
Q4 24
$17.3M
$-8.1M
Q3 24
$1.4M
$-7.2M
Q2 24
$10.2M
$-12.8M
Free Cash Flow
JMSB
JMSB
RCEL
RCEL
Q1 26
Q4 25
$22.0M
$-6.1M
Q3 25
$1.2M
$-6.2M
Q2 25
$7.4M
$-10.8M
Q1 25
$6.6M
$-10.5M
Q4 24
$16.8M
$-9.7M
Q3 24
$1.3M
$-11.0M
Q2 24
$10.1M
$-15.4M
FCF Margin
JMSB
JMSB
RCEL
RCEL
Q1 26
Q4 25
134.7%
-34.7%
Q3 25
7.3%
-36.1%
Q2 25
47.8%
-58.4%
Q1 25
45.3%
-56.9%
Q4 24
116.9%
-52.7%
Q3 24
9.5%
-56.1%
Q2 24
80.1%
-101.6%
Capex Intensity
JMSB
JMSB
RCEL
RCEL
Q1 26
Q4 25
3.4%
3.8%
Q3 25
0.2%
5.5%
Q2 25
1.0%
2.8%
Q1 25
2.3%
1.2%
Q4 24
3.4%
8.8%
Q3 24
0.8%
19.2%
Q2 24
0.4%
17.5%
Cash Conversion
JMSB
JMSB
RCEL
RCEL
Q1 26
Q4 25
3.82×
Q3 25
0.23×
Q2 25
1.48×
Q1 25
1.45×
Q4 24
3.61×
Q3 24
0.33×
Q2 24
2.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

JMSB
JMSB

Net Interest Income$16.5M98%
Noninterest Income$284.0K2%

RCEL
RCEL

Segment breakdown not available.

Related Comparisons